%	O
%	O
TITLE	O

Next	O
-	O
generation	O
sequencing	O
for	O
simultaneous	O
determination	O
of	O
human	O
papillomavirus	O
load	O
,	O
subtype	O
,	O
and	O
associated	O
genomic	O
copy	O
number	O
changes	O
in	O
tumors	O
.	O

%	O
%	O
ABSTRACT	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
in	O
cases	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oropharynx	O
is	O
a	O
powerful	O
predictive	O
and	O
prognostic	O
biomarker	O
.	O

We	O
describe	O
how	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
can	O
provide	O
a	O
novel	O
method	O
for	O
the	O
detection	O
of	O
HPV	O
in	O
DNA	O
isolated	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	B-HPV_Sample_Type
.	I-HPV_Sample_Type

Using	O
this	O
methodology	O
in	O
a	O
cohort	B-Study_Cohort
of	I-Study_Cohort
44	I-Study_Cohort
head	I-Study_Cohort
and	I-Study_Cohort
neck	I-Study_Cohort
tumors	I-Study_Cohort
,	O
we	O
identified	O
the	O
samples	B-HPV_Sample_Type
that	O
contained	O
HPV	O
sequences	O
,	O
the	O
viral	O
subtype	O
involved	O
,	O
and	O
a	O
direct	O
readout	O
of	O
viral	O
load	O
.	O

Specificity	O
of	O
HPV	O
detection	O
by	O
sequencing	O
compared	O
to	O
traditional	O
detection	O
methods	O
using	O
either	O
PCR	B-HPV_Lab_Technique
or	O
p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
was	O
100	O
%	O
.	O

Sensitivity	O
was	O
50	O
%	O
when	O
either	O
compared	O
to	O
PCR	B-HPV_Lab_Technique
[	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
29	O
%	O
to	O
71	O
%	O
]	O
or	O
75	O
%	O
when	O
compared	O
to	O
p16	O
(	O
CI	O
=	O
47	O
%	O
to	O
91	O
%	O
)	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
the	O
ability	O
of	O
next	O
-	O
generation	O
sequencing	O
to	O
detect	O
other	O
HPV	O
subtypes	O
that	O
would	O
not	O
have	O
been	O
detected	O
by	O
traditional	O
methods	O
,	O
and	O
we	O
demonstrated	O
the	O
ability	O
to	O
apply	O
this	O
method	O
to	O
any	O
tumor	O
and	O
any	O
virus	O
in	O
a	O
panel	O
of	O
eight	O
human	O
cancer	O
cell	O
lines	O
.	O

This	O
methodology	O
also	O
provides	O
a	O
tumor	O
genomic	O
copy	O
number	O
karyogram	O
,	O
and	O
in	O
the	O
samples	B-HPV_Sample_Type
analyzed	O
here	O
,	O
a	O
lower	O
level	O
of	O
chromosome	O
instability	O
was	O
detected	O
in	O
HPV	O
-	O
positive	O
tumors	O
compared	O
to	O
HPV	O
-	O
negative	O
tumors	O
,	O
as	O
observed	O
in	O
previous	O
studies	O
.	O

Thus	O
,	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
for	O
the	O
detection	O
of	O
HPV	O
provides	O
a	O
multiplicity	O
of	O
data	O
with	O
clinical	O
significance	O
in	O
a	O
single	O
test	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Cell	O
Lines	O
for	O
DNA	O
Extraction	O

Cell	O
lines	O
were	O
used	O
as	O
a	O
measure	O
of	O
the	O
specificity	O
of	O
detection	O
of	O
HPV	O
by	O
NGS	O
.	O

LUDLU	O
-	O
1	O
is	O
derived	O
from	O
lung	O
SCC	O
,	O
and	O
AGLCL	O
is	O
its	O
matching	O
B	O
lymphoblast	O
cell	O
line	O
.	O
NCI	O
-	O
H1437	O
is	O
derived	O
from	O
lung	O
adenocarcinoma	O
,	O
and	O
similarly	O
,	O
B1437	O
is	O
its	O
matching	O
B	O
lymphoblast	O
cell	O
line	O
.	O

HONE	O
-	O
1	O
is	O
derived	O
from	O
nasopharyngeal	O
SCCand	O
was	O
a	O
gift	O
from	O
Dr	O
.	O
Maria	O
Kost	O
-	O
Alimova	O
.	O

A549	O
is	O
derived	O
from	O
alveolar	O
cell	O
carcinoma	O
.	O
SiHa	O
and	O
CaSki	O
are	O
both	O
derived	O
from	O
cervical	O
SCC	O
and	O
are	O
known	O
to	O
contain	O
HPV	O
.	O

These	O
were	O
a	O
gift	O
from	O
Dr	O
.	O
Nicholas	O
Colman	O
.	O

KYSE	O
-	O
70	O
is	O
derived	O
from	O
esophageal	O
SCC	O
.	O
All	O
cell	O
lines	O
were	O
cultured	O
using	O
standard	O
cell	O
culture	O
techniques	O
.	O

DNA	O
was	O
prepared	O
from	O
1	O
to	O
7	O
x	O
106	O
cells	O
by	O
standard	O
phenol	O
-	O
chloroform	O
extraction	O
.	O

Patient	O
Samples	B-HPV_Sample_Type

Patients	B-Study_Cohort
included	I-Study_Cohort
in	I-Study_Cohort
this	I-Study_Cohort
study	I-Study_Cohort
were	I-Study_Cohort
diagnosed	I-Study_Cohort
with	I-Study_Cohort
SCC	I-Study_Cohort
of	I-Study_Cohort
the	I-Study_Cohort
head	I-Study_Cohort
and	I-Study_Cohort
neck	I-Study_Cohort
,	O
and	O
treated	O
with	O
chemora	O
-	O
diotherapy	O
at	O
the	O
Yorkshire	B-Study_Location
Cancer	O
Centre	O
between	O
2003	B-Study_Time
and	I-Study_Time
2006	I-Study_Time
(	O
ethics	O
approval	O
:	O
REC07	O
/	O
Q1206	O
/	O
30	O
)	O
.	O

In	O
total	O
,	O
52	O
patient	O
samples	B-HPV_Sample_Type
were	O
identified	O
for	O
this	O
study	O
.	O

The	O
patient	O
demographics	O
are	O
summarized	O
in	O
Supplemental	O
Table	O
S1	O
(	O
available	O
at	O
)	O
.	O

Of	B-Study_Cohort
the	I-Study_Cohort
52	I-Study_Cohort
pa	I-Study_Cohort
-	I-Study_Cohort
tient	I-Study_Cohort
samples	I-Study_Cohort
identified	I-Study_Cohort
,	I-Study_Cohort
44	I-Study_Cohort
were	I-Study_Cohort
suitable	I-Study_Cohort
for	I-Study_Cohort
inclusion	I-Study_Cohort
in	I-Study_Cohort

the	I-Study_Cohort
study	I-Study_Cohort
based	O
on	O
the	O
presence	O
of	O
SCC	O
in	O
their	O
FFPE	O
block	O
.	O

Of	O
the	O
44	O
tumors	O
sampled	O
,	O
there	O
were	O
20	O
OP	O
,	O
12	O
laryngeal	O
,	O
8	O
hypopharyngeal	O
,	O
and	O
4	O
oral	O
samples	B-HPV_Sample_Type
.	O

For	O
DNA	O
extraction	O
,	O
a	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
-	O
stained	O
slide	O
was	O
cut	O
from	O
each	O
FFPE	O
block	O
and	O
tumor	O
areas	O
marked	O
by	O
a	O
pathologist	O
.	O

Ten	O
7	O
-	O
µm	O
sections	O
were	O
then	O
serially	O
cut	O
onto	O
plain	O
glass	O
slides	O
,	O
and	O
after	O
dewax	O
-	O
ing	O
and	O
rehydration	O
of	O
the	O
sections	O
,	O
the	O
tumor	O
tissue	B-HPV_Sample_Type
was	O
macrodissected	O
using	O
a	O
sterile	O
scalpel	O
blade	O
and	O
the	O
marked	O
H	O
&	O
E	O
slide	O
as	O
a	O
guide	O
.	O

DNA	O
extraction	O
was	O
per	O
-	O
formed	O
on	O
dissected	O
tissue	B-HPV_Sample_Type
using	O
the	O
QIAamp	O
DNA	O
mini	O
kit	O
(	O
Qiagen	O
,	O
Crawley	O
,	O
UK	O
)	O
according	O
to	O
the	O
manufactur	O
-	O
er’s	O
instructions	O
and	O
quantified	O
using	O
the	O
Nanodrop	O
-	O
8000	O
(	O
Thermo	O
Scientific	O
,	O
Loughborough	O
,	O
UK	O
)	O
and	O
the	O
Quant	O
-	O
iT	O
dsDNA	O
BR	O
assay	O
(	O
Life	O
Technologies	O
,	O
Paisley	O
,	O
UK	O
)	O
.	O

HPV	O
Detection	O
by	O
PCR	B-HPV_Lab_Technique

Detection	O
of	O
HPV	O
sequences	O
was	O
performed	O
on	O
patient	O
samples	B-HPV_Sample_Type
in	O
two	O
separate	O
PCRs	B-HPV_Lab_Technique
using	O
two	O
different	O
sets	O
of	O
primers	O
:	O
a	O
generic	O
set	O
(	O
GP5	O
/	O
GP6	O
)	O
widely	O
used	O
to	O
detect	O
all	O
HPV	O
subtypes	O
(	O
F	O
:	O
5	O
-	O
TTTGTTACTGTGG	O
-	O
TAGATACTAC	O
-	O
3	O
,	O
R	O
:	O
5	O
-	O
GAAAAATAAACTGTAAATCAT	O
-	O

ATTC	O
-	O
3	O
)	O
and	O
an	O
HPV16	O
-	O
specific	O
set	O
(	O
F	O
:	O
5	O
-	O
TCAAAA	O
-	O
GCCACTGTGTCCTG	O
-	O
3	O
,	O
R	O
:	O
5	O
-	O
CGTGTTCTTGATGATCT	O
-	O

GCA	O
-	O
3	O
)	O
.	O

A	O
control	O
PCR	B-HPV_Lab_Technique
of	O
a	O
79	O
-	O
bp	O
fragment	O
of	O
fJ	O
-	O
globin	O
(	O
HBB	O
)	O
was	O
also	O
performed	O
(	O
F	O
:	O
5	O
-	O
GGATCCTTCTCTTGT	O
-	O
GTTGG	O
-	O
3	O
,	O
R	O
:	O
5	O
-	O
CTACCATTGGAAAAGCAACC	O
-	O
3	O
)	O
.	O

Re	O
-	O

actions	O
containing	O
1x	O
Amplitaq	O
Gold	O
PCR	B-HPV_Lab_Technique
buffer	O
,	O
3	O
mmol	O
/	O
L	O
magnesium	O
chloride	O
,	O
1	O
µmol	O
/	O
L	O
of	O
each	O
primer	O
,	O

0	O
.	O
4	O
mmol	O
/	O
L	O
deoxynucleotide	O
triphosphates	O
(	O
dNTPs	O
)	O
,	O
2	O
U	O
of	O
Amplitaq	O
Gold	O
DNA	O
polymerase	O
(	O
Life	O
Technologies	O
)	O
,	O
and	O
2	O
ng	O
of	O
DNA	O
were	O
prepared	O
in	O
a	O
volume	O
of	O
25	O
µL	O
.	O

PCR	B-HPV_Lab_Technique
conditions	O
were	O
:	O
9	O
minutes	O
at	O
93°C	O
;	O
40	O
cycles	O
of	O
94°C	O
for	O
20	O
seconds	O
,	O
53°C	O
for	O
20	O
seconds	O
,	O
and	O
72°C	O
for	O
40	O
seconds	O
;	O
then	O
72°C	O
for	O
7	O
minutes	O
.	O

PCR	O
products	O
were	O
visualized	O
on	O
4	O
%	O
agarose	O
gels	O
and	O
scored	O
for	O
the	O
presence	O
or	O
ab	O
-	O
sence	O
of	O
bands	O
of	O
79	O
bp	O
(	O
HBB	O
)	O
,	O
150	O
bp	O
(	O
generic	B-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O
,	O
and	O
120	O
bp	O
(	O
HPV	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
16	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique
of	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique

Immunohistochemistry	B-HPV_Lab_Technique
for	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
protein	I-HPV_Lab_Technique
expres	O
-	O
sion	O
as	O
a	O
marker	O
for	O
HPV	O
infection	O
in	O
patient	O
samples	B-HPV_Sample_Type
was	O
performed	O
using	O
the	O
CINtec	B-HPV_Lab_Technique
Histology	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MTM	I-HPV_Lab_Technique
Laborato	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
ries	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Heidelberg	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Germany	I-HPV_Lab_Technique
)	O
using	O
half	O
volumes	O
for	O
all	O
steps	O
and	O
following	O
the	O
manufacturer’s	O
instructions	O
.	O

The	O
primary	O
antibody	O
is	O
a	O
monoclonal	O
mouse	O
anti	O
-	O
human	O
p16INK4a	O
an	O
-	O
tibody	O
,	O
Clone	O
E6H4	O
.	O

An	O
FFPE	O
bladder	O
tumor	O
with	O
high	O
p16	O
expression	O
was	O
used	O
as	O
a	O
positive	O
control	O
,	O
and	O
a	O
normal	O
FFPE	O
tonsil	O
as	O
a	O
negative	O
control	O
.	O

Two	O
pathologists	O
blinded	O
to	O
HPV	O
status	O
assessed	O
the	O
staining	O
,	O
and	O
a	O
score	O
of	O
positive	O
was	O
recorded	O
when	O
moderate	O
-	O
to	O
-	O
strong	O
staining	O
over	O

>	O
70	O
%	O
of	O
the	O
tumor	O
cells	O
was	O
observed	O
.	O

Sequencing	O
and	O
Alignment	O

Libraries	O
were	O
prepared	O
for	O
Illumina	O
sequencing	O
from	O
each	O
DNA	O
sample	B-HPV_Sample_Type
using	O
100	O
ng	O
to	O
1	O
µg	O
of	O
DNA	O
,	O
following	O
recently	O
described	O
protocols	O
.	O
Equal	O
amounts	O
of	O
each	O
library	O
passing	O
quality	O
control	O
were	O
multiplexed	O
to	O
10	O

Table	O
1	O
.	O

Summary	O
of	O
Sequencing	O
Results	O

Results	O
for	O
cell	O
lines	O
are	O
shown	O
at	O
the	O
top	O
,	O
followed	O
by	O
patient	O
samples	B-HPV_Sample_Type
.	I-HPV_Sample_Type

For	O
each	O
sample	B-HPV_Sample_Type
,	O
the	O
numbers	O
of	O
viral	O
and	O
human	O
reads	O
obtained	O
are	O
given	O
.	O

From	O
the	O
number	O
of	O
human	O
reads	O
,	O
and	O
assuming	O
a	O
diploid	O
genome	O
,	O
the	O
density	O
of	O
reads	O
in	O
kb	O
per	O
read	O
is	O
calculated	O
.	O

Given	O
a	O
known	O
HPV	O
genome	O
size	O
of	O
7	O
.	O
9	O
kb	O
and	O
the	O
density	O
of	O
reads	O
,	O
the	O
amount	O
of	O
HPV	O
genome	O
is	O
given	O
,	O
first	O
as	O
the	O
kb	O
of	O
viral	O
sequence	O
,	O
then	O
as	O
the	O
number	O
of	O
viral	O
copies	O
or	O
viral	O
load	O
.	O

Finally	O
,	O
the	O
detectable	O
viral	O
load	O
with	O
95	O
%	O
confidence	O
given	O
the	O
total	O
number	O
of	O
reads	O
is	O
calculated	O
.	O

samples	B-HPV_Sample_Type
per	O
lane	O
for	O
76	O
-	O
bp	O
sequencing	O
,	O
each	O
read	O
con	O
-	O
taining	O
70	O
bp	O
of	O
genomic	O
DNA	O
sequence	O
and	O
6	O
bp	O
of	O
tagged	O
adapter	O
.	O

Reads	O
were	O
sorted	O
into	O
files	O
according	O
to	O
their	O
unique	O
tag	O
and	O
stripped	O
of	O
the	O
tag	O
sequence	O
,	O
aligned	O
to	O
both	O
the	O
human	O
reference	O
genome	O
(	O
UCSC	O
version	O
hg19	O
,	O
,	O
last	O
accessed	O
April	O
26	O
,	O
2010	O
)	O
and	O
to	O
either	O
all	O
known	O
HPV	O
subtypes	O
(	O
patient	O
samples	B-HPV_Sample_Type
)	O
or	O
all	O
known	O
viral	O
genomes	O
(	O
cell	O
lines	O
only	O
)	O
downloaded	O
from	O
the	O
National	O
Center	O
for	O
Biotech	O
-	O
nology	O
Information	O
(	O

,	O
last	O
accessed	O
Novem	O
-	O
ber	O
26	O
,	O
2010	O
)	O
using	O
the	O
Burrows	O
-	O
Wheeler	O
Aligner	O
and	O

alignments	O
stored	O
in	O
SAM	O
format	O
.	O

See	O
for	O
the	O
range	O
of	O
human	O
and	O
viral	O
reads	O
obtained	O
for	O
each	O
sample	B-HPV_Sample_Type
.	I-HPV_Sample_Type

Whole	O
-	O
Genome	O
Copy	O
Number	O
Analysis	O

Copy	O
number	O
for	O
the	O
human	O
DNA	O
was	O
calculated	O
as	O
previously	O
described	O
.	O
Briefly	O
,	O
human	O
reads	O
were	O
sorted	O

by	O
chromosome	O
and	O
position	O
.	O

The	O
ratio	O
of	O
test	O
to	O
control	O
reads	O
in	O
windows	O
of	O
equal	O
size	O
averaging	O
400	O
reads	O
was	O
calculated	O
across	O
the	O
genome	O
.	O

The	O
control	O
sample	B-HPV_Sample_Type
was	O
constructed	O
from	O
a	O
pool	O
of	O
20	O
normal	O
British	O
individuals	O
downloaded	O
from	O
the	O
1000	O
Genomes	O
Project	O
(	O
,	O
last	O
accessed	O
,	O
March	O
03	O
,	O
2011	O
)	O
.	O

Frequency	O
plots	O
comparing	O
HPV	O
-	O
positive	O
and	O

-	O
negative	O
tumors	O
were	O
drawn	O
by	O
counting	O
how	O
many	O
samples	B-HPV_Sample_Type
exceeded	O
a	O
±0	O
.	O
25	O
log2	O
tumor	O
/	O
normal	O
ratio	O
along	O
the	O
genome	O
(	O
HPV	O
status	O
determined	O
by	O
sequence	O
detection	O
)	O
.	O

HPV	O
Detection	O
and	O
Load	O
Measurements	O
by	O
Sequencing	O

To	O
measure	O
HPV	O
viral	O
load	O
,	O
the	O
number	O
of	O
reads	O
align	O
-	O
ing	O
to	O
the	O
human	O
and	O
HPV	O
genomes	O
were	O
counted	O
.	O

To	O
avoid	O
false	O
positives	O
,	O
only	O
reads	O
aligning	O
with	O
the	O
highest	O
Burrows	O
-	O
Wheeler	O
Alignment	O
mapping	O
score	O
of	O
37	O
that	O
did	O

Figure	O
1	O
.	O

The	O
statistically	O
detectable	O
viral	O
load	O
for	O
increasing	O
numbers	O
of	O
reads	O
.	O

The	O
lines	O
indicate	O
the	O
minimum	O
detectable	O
numbers	O
of	O
viruses	O
per	O
cell	O
for	O
different	O
read	O
numbers	O
for	O
three	O
different	O
probabilities	O
.	O

not	O
align	O
better	O
to	O
the	O
human	O
genome	O
were	O
used	O
.	O

We	O
can	O
estimate	O
the	O
minimum	O
number	O
of	O
viral	O
genomes	O
from	O
the	O
observed	O
number	O
of	O
viral	O
reads	O
.	O

If	O
we	O
had	O
an	O
infinitely	O
large	O
number	O
of	O
reads	O
,	O
the	O
fraction	O
,	O
or	O
expected	O
fre	O
-	O
quency	O
of	O
viral	O
reads	O
would	O
be	O
:	O

VGS	O

µ=	O
NVIG	O
x	O
HGS	O
,	O

where	O
VGS	O
=	O
viral	O
genome	O
size	O
,	O
HGS	O
=	O
human	O
genome	O
size	O
,	O
and	O
NVIG	O
=	O
number	O
of	O
viral	O
genomes	O
.	O

In	O
a	O
sample	O
of	O
N	O
reads	O
,	O
the	O
expected	O
number	O
of	O
reads	O
is	O
:	O

A=	O
round	O
µx	O
N	O

or	O

value	O
of	O
A	O
for	O
any	O
value	O
of	O
k	O
and	O
calculate	O
the	O
cumulative	O
probability	O
of	O
observing	O
k	O
or	O
fewer	O
reads	O
.	O

P	O
i	O
,	O
A	O

In	O
this	O
way	O
,	O
we	O
can	O
estimate	O
the	O
number	O
of	O
virus	O
genomes	O
that	O
would	O
produce	O
the	O
observed	O
reads	O
.	O

We	O
can	O
see	O
from	O
,	O
for	O
example	O
,	O
that	O
if	O
a	O
sample	B-HPV_Sample_Type
has	O
10	O
viral	O
copies	O
per	O
cell	O
,	O
approximately	O
250	O
,	O
000	O
reads	O
are	O
needed	O
to	O
detect	O
at	O
least	O
one	O
viral	O
sequence	O
with	O
a	O
95	O
%	O
confidence	O
.	O

Similarly	O
,	O
500	O
,	O
000	O
reads	O
are	O
needed	O
to	O
detect	O
5	O
viral	O
copies	O
per	O
cell	O
and	O
1	O
million	O
reads	O
can	O
detect	O
3	O
viral	O
copies	O
per	O
cell	O
at	O
95	O
%	O
confidence	O
.	O

The	O
same	O
numbers	O
of	O
reads	O
can	O
detect	O
smaller	O
viral	O
loads	O
with	O
correspondingly	O
smaller	O
probabilities	O
.	O

The	O
number	O
of	O
detectable	O
human	O
reads	O
for	O
each	O
sample	B-HPV_Sample_Type
can	O
be	O
seen	O
in	O
.	O

Episomal	O
and	O
integrated	O
viral	O
genomes	O
are	O
indistinguishable	O
at	O
this	O
low	O
read	O
depth	O
.	O

